• 5 min read
• Published on 15 August 2025
Listen to article
6:16Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
It’s a funny old world, isn’t it. A politician in Washington D.C. gets a bit hot under the collar about drug prices, and suddenly a patient in Manchester has to fork out more for their prescription. To me, this isn't just a headline, it’s a perfect, almost comical, illustration of how global markets really work. When you squeeze a business in one place, the pressure simply pops up somewhere else. And for those of us paying attention, that pressure can create some rather interesting opportunities.
Let’s talk about Eli Lilly. The company has a blockbuster weight-loss drug called Mounjaro, and it found itself in the crosshairs of American lawmakers demanding lower prices. A noble cause, I suppose. But what did Lilly do? Did they dutifully tighten their belts and accept a smaller slice of the pie? Of course not. Instead, they played a rather clever, if cynical, game. They hiked the price of Mounjaro in other countries, including right here in the UK, to make up for the shortfall.
I find this fascinating. It’s a clear signal that for Big Pharma, the world is one big balance sheet. A loss in one column must be offset by a gain in another. This isn't just about one company or one drug. It’s a new playbook for an industry under constant political scrutiny. They’ve shown that when pushed, they won’t just absorb the cost, they’ll redistribute it. This whole affair, which I’ve been tracking in what I call The Global Weight-Loss Drug Price Shift, sets a fascinating precedent for investors.
So, what happens when the market leader suddenly makes its product significantly more expensive? Well, people start looking for alternatives. It’s human nature. Eli Lilly might have solved its American political problem, but in doing so, it may have just rolled out the red carpet for its competitors in Europe and beyond. A dominant position is only dominant if people can afford to buy into it.
This is where things could get interesting. You have companies like Lexicon Pharmaceuticals, which is busy developing its own treatments for metabolic conditions. Then there’s Esperion Therapeutics, working on therapies that sit in a similar universe. I’m not saying these are guaranteed winners, far from it. But when a giant like Lilly creates a price vacuum, smaller, more nimble companies with effective and more reasonably priced alternatives could be drawn into the light. It’s a classic market disruption scenario, and these are precisely the moments when fortunes can shift.
For any investor in the pharmaceutical sector, this changes the calculus. Regulatory risk has always been part of the deal, but now we have to add a layer of geopolitical price-shuffling to our analysis. A company’s fortunes may no longer depend solely on the efficacy of its drugs, but on its ability to navigate a complex web of international politics and pricing strategies.
The underlying demand for weight-loss treatments isn’t going anywhere, let’s be clear about that. The market is enormous and will likely continue to grow. The question is no longer just about who has the best product, but who has the smartest, most sustainable global strategy. Companies that are overly reliant on a single market, particularly the US, might look a bit more fragile now. Those with a diverse geographical footprint and a sensible approach to pricing could prove to be the more resilient bets in the long run. It’s a new game, with new rules. And for the shrewd investor, that’s always a welcome challenge.
View the full Basket:The Global Weight-Loss Drug Price Shift
View the full Basket:The Global Weight-Loss Drug Price Shift
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article